Possible role of SCN4A skeletal muscle mutation in apnoea during seizure by Türkdoğan, D et al.
Epilepsia Open. 2019;00:1–6.    | 1wileyonlinelibrary.com/journal/epi4
Received: 20 November 2018 | Revised: 20 May 2019 | Accepted: 8 June 2019
DOI: 10.1002/epi4.12347  
S H O R T  R E S E A R C H  A R T I C L E
Possible role of SCN4A skeletal muscle mutation in apnea during 
seizure
Dilşad Türkdoğan1 |   Emma Matthews2  |   Sunay Usluer3 |   Aslı Gündoğdu4 |   
Kayıhan Uluç5 |   Roope Mannikko2 |   Michael G. Hanna2 |   Sanjay M. Sisodiya6,7  |   
Hande S. Çağlayan4,8
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors. Epilepsia Open published by Wiley Periodicals Inc. on behalf of International League Against Epilepsy.
Türkdoğan and Matthews contributed equally to the work. 
1Medical Faculty, Department of Child 
Neurology, Marmara University, Istanbul, 
Turkey
2Queen Square Centre for Neuromuscular 
Diseases, UCL Queen Square Institute of 
Neurology, UCL and National Hospital for 
Neurology and Neurosurgery, London, UK
3Formerly Affiliated with Department of 
Molecular Biology and Genetics, Boğaziçi 
University, Istanbul, Turkey
4Department of Molecular Biology and 
Genetics, Boğaziçi University, Istanbul, 
Turkey
5Medical Faculty, Department of Clinical 
Neurophysiology and Neurology, Marmara 
University, Istanbul, Turkey
6Department of Clinical and Experimental 
Epilepsy, UCL Queen Square Institute of 
Neurology, London, UK
7Chalfont Centre for Epilepsy, Bucks, UK
8İzmir Biomedicine and Genome Center, 
İzmir, Turkey
Correspondence
Sanjay M. Sisodiya, Department of Clinical 
and Experimental Epilepsy, UCL Queen 
Square Institute of Neurology, London, UK.
Email: s.sisodiya@ucl.ac.uk
Funding information
Boğaziçi University Research Fund, Grant/
Award Number: 10B01D13
Abstract
SCN4A gene mutations cause a number of neuromuscular phenotypes including my-
otonia. A subset of infants with myotonia‐causing mutations experience severe life‐
threatening episodic laryngospasm with apnea. We have recently identified similar 
SCN4A mutations in association with sudden infant death syndrome. Laryngospasm 
has also been proposed as a contributory mechanism to some cases of sudden unex-
pected death in epilepsy (SUDEP). We report an infant with EEG‐confirmed seizures 
and recurrent apneas. Whole‐exome sequencing identified a known pathogenic mu-
tation in the SCN4A gene that has been reported in several unrelated families with 
myotonic disorder. We propose that the SCN4A mutation contributed to the apneas 
in our case, irrespective of the underlying cause of the epilepsy. We suggest this sup-
ports the notion that laryngospasm may contribute to some cases of SUDEP, and im-
plicates a possible shared mechanism between a proportion of sudden infant deaths 
and sudden unexpected deaths in epilepsy.
K E Y W O R D S
laryngospasm, SUDEP, myotonia, sodium channel
2 |   TÜRKDOĞAN eT Al.
1 |  INTRODUCTION
The SCN4A gene codes for the alpha sub‐unit of the volt-
age‐gated sodium channel Nav1.4, which is essential for 
muscle membrane excitability and contraction.1 It is the 
only sodium channel isoform expressed in adult skeletal 
muscle. Mutations of SCN4A are consequently associ-
ated with a range of neuromuscular phenotypes without 
systemic involvement, including autosomal‐dominant 
myotonia, and/or periodic paralysis, and autosomal reces-
sive congenital myasthenia and congenital myopathy.1‒3 
Respiratory and laryngeal muscle compromise is common 
in affected infants and children and can cause life‐threat-
ening respiratory impairment including recurrent apneas.4 
The autosomal‐dominant SCN4A disorders such as myo-
tonia are episodic. Infants with SCN4A‐related myotonia 
can appear outwardly healthy but present acutely with re-
current episodes of generalized stiffening of the trunk and 
limbs, apnea, and cyanosis (due to respiratory and laryn-
geal muscle myotonia‐causing laryngospasm) which may 
be accompanied by bradycardia and loss of consciousness. 
This specific myotonic phenotype has been named severe 
neonatal episodic laryngospasm5 (SNEL). An erroneous 
diagnosis of generalized epilepsy is frequently made in 
these infants.6 Events can be life‐threatening or “near miss” 
with several infants requiring ventilation and prolonged 
ITU admissions.5,7 Such acute life‐threatening events re-
cently led us to investigate SCN4A gene mutations in cases 
of sudden infant death. We found a small but significant 
proportion of cases carried rare functionally deleterious 
variants. Laryngospasm has also been proposed as a con-
tributory mechanism in sudden unexpected death in epi-
lepsy (SUDEP).9‒12
Here, we report a child who was investigated and treated 
for generalized seizures associated with apneic spells and was 
found to carry the heterozygous p.A1156T SCN4A mutation. 
This mutation has been reported in several independent fam-
ilies with myotonia, and functional studies have confirmed 
its pathogenicity.13‒15 We hypothesize that SCN4A mutation 
may contribute to apnea during the physiological stress of 
seizures.
2 |  CASE REPORT
Written informed consent was obtained from the family for 
this case study. A male infant presented with episodes begin-
ning at 35  days of age that were triggered by feeding and 
characterized by facial flushing, apnea, and cyanosis fol-
lowed by stiffening of the lower limbs lasting up to 20 sec-
onds. A cluster of six similar events, all with apnea, and 
reported by his mother, occurred over three consecutive days. 
Pre‐, peri‐, and post‐natal history was unremarkable. He had 
normal neurological examination at 39 days of age. Cardiac 
evaluation including echocardiogram and ECG was also nor-
mal. He was admitted for further investigation and teleme-
try. EEG examination captured a focal seizure characterized 
by opening of the eyes, version of the head to the left side, 
flushing and evolving cyanosis of the face with tonic con-
traction of the lower extremities. Ictal EEG activity lasting 
15 seconds originated from the left temporal region. Serial 
interictal EEG examinations done at two and three months 
of age showed multifocal sharp waves from the left hemi-
sphere (Figure 1). Following phenobarbital loading, the sei-
zures immediately resolved. Metabolic screening and cranial 
MRI were unremarkable. Medical therapy was continued for 
13 months and then stopped, and no seizures have recurred.
In the subsequent follow‐up period, the child, currently 
nine years old, has been generally well with normal de-
velopmental milestones. No muscle weakness, cramps, or 
myotonia‐like symptoms have been reported. Neurological, 
including neuromuscular, examination and academic skills 
have been within normal limits except for mild attention defi-
cit disorder. The only family history reported was of the elder 
brother having a single febrile seizure. As no specific cause 
for the seizures was identified, genetic investigations were 
undertaken.
2.1 | Methods
DNA was extracted from 10  mL peripheral blood using 
standard procedures. Coding sequences and exon/in-
tron boundaries of two candidate genes, SCN2A and 
KCNQ2, were amplified by PCR as described previ-
ously16 and Sanger‐sequenced. Whole‐exome sequencing 
was performed using the NimbleGen EZ Whole Exome 
Enrichment Kit on the Illumina HiSeq2000 platform with 
100X coverage. Sequence annotation and variant calling 
were done on Genomize SEQ platform (https ://seq.genom 
ize.com), and variant prioritization was done at MAF <1% 
in all normal populations. ClinVar associations and all de-
structive and missense variants were filtered from genes in 
Epilepsy_HPO_September 2018 and/or MORBID OMIM 
May 2018. PCR and Sanger sequencing were performed 
to confirm the SCN4A c.G3466A nucleotide change in the 
proband and for segregation analysis in the family using 
primers: F: 5′‐CCCACGTTGTCGTAGTTGAC‐3′ and R: 
5′‐TGGGTGGCGTAGAGATGTGG‐3′.
2.2 | Results
Candidate gene and WES analysis of epilepsy genes and 
others expressed in the brain did not demonstrate any 
known pathogenic or potentially pathogenic variants. 
Filtering for ClinVar associated variants in MORBID 
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OMIM 2018 revealed a previously reported heterozygous 
SCN4A variant c.G3466A, p.A1156T.12,13 This variant was 
inherited paternally and confirmed in the proband's father 
(Figure 2D). The father denied any symptoms of myopathy 
and/or myotonia, and none were demonstrated on clinical 
examination. The father's nerve conduction study param-
eters of latency, amplitude, and velocity were found to be 
within normal limits, but delayed lower amplitude motor 
responses following the compound motor action potential, 
indicating post‐exercise myotonic potentials, were ob-
served (Figure 2C). Needle EMG revealed myotonic po-
tentials lasting more than 300 milliseconds in all sampled 
muscles (Figure 2A,B). The child's parents did not wish 
him to undergo an EMG examination.
3 |  DISCUSSION
Several cases of infantile SCN4A myotonia with laryn-
gospasm and apnea have been reported to be erroneously 
diagnosed as generalized seizures, delaying appropriate 
therapy.6 We initially re‐examined the clinical, EEG, and 
WES data from this case with this possibility in mind. 
However, EEG clearly demonstrated epileptiform dis-
charges during symptoms and interictally. The WES data 
confirm the infant does carry a paternally inherited known 
pathogenic SCN4A mutation, shown previously to be func-
tionally deleterious, with neurophysiological evidence of 
myotonia in the father. The p.A1156T mutation has been 
described to cause myotonia and periodic paralysis with 
variable severity in several unrelated families. The larg-
est series described several cases in which myotonia or 
increased insertional activity was only detected by neu-
rophysiology, without overt clinical symptoms, and in 
others who complained of more obscure symptoms of my-
algia.13 This is compatible with the history in the father of 
our proband; he reported no significant clinical symptoms 
but had EMG evidence of myotonia, an abnormal finding 
that supports a myotonic disorder. Functional studies have 
confirmed a clear deleterious impact of this mutation on 
channel function, with impaired fast inactivation and accel-
erated recovery from inactivation.13 A gain‐of‐function ef-
fect mediated via impaired fast inactivation is the hallmark 
of all SCN4A myotonia‐causing mutations.1 The p.A1156T 
mutation is present at low frequency (15 individuals) in the 
gnomAD database. However, considering that this variant 
can be associated with neurophysiology evidence of myo-
tonia without overt clinical symptoms (as is the case of the 
proband's father), asymptomatic cases might have been in-
cluded in large population datasets, such as gnomAD. It 
F I G U R E  1  EEG examination at 2 months of age showed repetitive sharp waves at left occipital region (A) and left temporal region (B). EEG 
examination at 3 months of age showed sharp waves at left frontal (C) and left temporal region (D)
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has been clearly established to cause myotonia but the vari-
able clinical expression suggests other genetic and epige-
netic factors may contribute to overall severity.
We recently described a similar gain‐of‐function muta-
tion in sudden infant death,8 and such mutations are a rec-
ognized cause of recurrent life‐threatening apneas in infants 
with myotonia and laryngospasm.4,5 In children with the lat-
ter, there is clear evidence that the muscle phenotype evolves 
with age; that is, apneas are prominent and symptomatic in 
early life but diminish with age.6
The clinical presentation of infantile myotonia with la-
ryngospasm can easily be mistaken for generalized epilepsy.6 
Myotonia is a crucial diagnosis to make as it is eminently 
treatable with sodium channel blockers. We would advocate 
that myotonia be at least considered in the differential diag-
nosis of infants presenting with recurrent events with asso-
ciated apnea in the presence or absence of telemetry‐proven 
seizures. We propose that our case illustrates a further clin-
ical scenario, of epileptic seizures of unknown cause, with 
a genuine comorbidity (apnea likely related to mutation in 
SCN4A).
Apnea and cyanosis can be an independent consequence 
of seizures, and we cannot definitively state that the SCN4A 
mutation in this case caused laryngospasm and contributed 
to the episodic apnea, and we do not suggest that the SCN4A 
mutation was the cause of the proband's epilepsy per se. 
We propose, however, that SCN4A mutations may contrib-
ute to apnea in infants during seizures of whatever cause. 
Recently, laryngospasm and upper airway obstruction have 
been shown to contribute to hypoxia and death in rat mod-
els of sudden unexpected death in epilepsy.9,12 There are 
also cases of ictal and post–ictal laryngospasm contribut-
ing to apnea and “near miss” events requiring intubation in 
adults with refractory epilepsy,10,11 further supporting the 
notion that laryngospasm may contribute to some cases of 
sudden unexpected death in epilepsy (SUDEP). This sug-
gests there may be a shared mechanism of upper airway 
obstruction between some cases of sudden infant death and 
sudden unexpected death in epilepsy, a hypothesis requir-
ing further testing.
There has been one other relevant case published of which 
we are aware. A rare SCN4A variant of uncertain significance 
F I G U R E  2  EMG examinations done in the father carrying the SCN4A variant showed increased insertional activity on upper (A) and lower 
extremity muscles (B) and delayed lower amplitude motor response following the compound motor action potential on median motor NCS (C) and 
Sanger sequencing results of the SCN4A c.G3466A variant in the family (D)
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has been reported in an individual with generalized epilepsy 
and a family history (deceased mother) of probable SUDEP.17 
The variant was not present in the proband's father but the 
mother's DNA was not tested.
Although often considered to be tissue‐specific, the ex-
pression pattern of sodium channel isoforms varies through-
out life. In adult skeletal muscle, Nav1.4 is the only isoform 
present but in infancy the cardiac muscle isoform Nav1.5 
is also expressed in skeletal muscle. Nav1.5 expression is 
downregulated during development but upregulated in de-
nervated adult muscle. Conversely cardiac muscle expresses 
Nav1.4 and Nav1.5 for a limited period, before Nav1.5 be-
comes the sole channel expressed. There is also evidence of 
the presence of Nav1.4 in the mouse and human brain, al-
though relative expression levels at different stages of life are 
unknown. In a family with a function‐changing Nav1.4 muta-
tion and CNS symptoms of tremor and epilepsy, the authors 
postulated this expression could increase the susceptibility to 
epilepsy.18 However, SCN4A mutations have so far not been 
associated with epilepsy pathogenesis.
In summary, we report a pathogenic SCN4A mutation, 
previously associated with myotonia, in a child with epilepsy 
and concurrent apneas. We propose the SCN4A mutation may 
contribute to the apneas via laryngeal and respiratory muscle 
myotonia. This is consistent with the notion that laryngo-
spasm may contribute to some cases of sudden unexpected 
death in epilepsy (SUDEP) and may suggest a shared mecha-
nism between some cases of sudden infant death and SUDEP. 
Our findings need exploration in other cohorts of patients 
who have succumbed to SUDEP, or have documented apnea 
or laryngospasm, irrespective of the putative cause of the 
epilepsy in such patients. SCN4A mutations may constitute 
genetic comorbidity, increasing risks of laryngospasm and 
attendant mechanical apnea during epileptic seizures. More 
data are required to determine this and any implications for 
the treatment and monitoring requirements of such patients.
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